RecruitingPhase 2NCT06500273
Blood
Primary mediastinal large B-cell lymphoma
45
studies recruiting now
as of 7 Sept 2026
162
studies registered in total
as of 7 Sept 2026
5
countries with a recruiting site
as of 7 Sept 2026
26 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07365306
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 2NCT06784726
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
RecruitingPhase 1 / Phase 2NCT07788118
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
RecruitingPhase 1 / Phase 2NCT06536049
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 45 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Primary mediastinal large B-cell lymphoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Primary mediastinal large B-cell lymphoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (BCL6, XPO1).
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).